The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Recruiting

• Conditions: Chronic Pancreatitis; FAP; Pancreatic Ductal Adenocarcinoma; Genetic Pancreatitis; Pancreatic Cyst; Fatty Pancreas; Familial Atypical Multiple Mole-Melanoma; Peutz-Jeghers Syndrome; Ataxia Telangiectasia; Genetic Pancreatic Cancer
• Interventions: Other: Data collection

• Registration Number: NCT05692596
• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Brief Summary

The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-06
• Study First Submitted: 2023-01-11
• Study First Submitted QC: 2023-01-11
• Study First Posted: 2023-01-20
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-03
• Last Update Posted: 2025-03-04
• Primary Completion: 2026-02
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• 18 years of age or older
• Moffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)
• Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.
• Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
All participants	Data collection	Participants include patients scheduled to see the clinical team in the Pancreas Interception Center (PIC) which will be housed in the Moffitt GI Clinic.

Primary Outcome Measures

Name	Time	Method
Database creation	24 months	A centralized, real-time, queryable and secure database will be developed that will integrate data on Moffitt patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), pancreatic cystic lesions (benign, pre-cancerous and malignant), or an inherited PDAC susceptibility.

Trial Locations

Locations (1)

Moffitt Cancer Center; 🇺🇸 Tampa, Florida, United States